Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Trial Profile

A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lixivaptan (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Adverse reactions
  • Acronyms ELISA
  • Sponsors Palladio Biosciences
  • Most Recent Events

    • 05 Nov 2019 According to Palladio Biosciences media release, data from this study will be presented at the American Society of Nephrologys Kidney Week 2019, to be held in Washington, D.C. on November 7-10.
    • 22 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Feb 2020.
    • 22 Oct 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top